Cancer Therapies: Technologies and Global Markets

SUMMARY

This report:

• Covers updated aspects in the oncology industry
• Reviews markets for each of the categories of reagents used to treat cancer and different therapies, including chemotherapy, immunotherapy, target therapy, and sex hormones
• Analyzes spending in the reagents and therapies categories worldwide
• Studies new and different types of regulations enforced by the authorities in the oncology field, new drugs, and recalls in the market
• Studies the market share of the different drug manufacturers and suppliers with an emphasis on the market leaders, as well as demand and use
• Emphasizes new technologies and their uses
• Examines new patents and their significance with a statistical description
• Details present and future (2013) trends in spending in the cancer therapy

Introduction

STUDY OBJECTIVES

BCC's goal in conducting this study is to provide an overview of the current and potential aspects of the global market for cancer therapies. The report determines the market size, market leaders, and factors affecting the market for cancer therapies with the inclusion of the market by disease sector.

The overview of types of diseases and different therapies in cancer is also examined along with sale figures over the 5-year period from 2008 to 2013. Companies manufacturing/selling the drugs to treat cancer are profiled, and the factors affecting markets for these products and how those markets are likely to change are analyzed. Revenues have been broken down by the type of therapies and by different regions.

Our key objective is to present a comprehensive analysis of the current and future market and to analyze the future direction of cancer therapies with an emphasis on newer products.

REASONS FOR DOING THIS STUDY

Due to continuous technology advances in research and development in the field of oncology and the requirement for newer and more effective pharmaceutical drugs/therapies, companies are investing in the development of these new products to lessen the side effects and target the disease. A fundamental change in cancer therapies is underway with a shift from the use of chemotherapy drugs to targeted therapy or the use of chemotherapy drugs along with targeted therapies. Targeted therapies are being developed for targeting cancer cells more specifically. Targeted therapies are more efficacious and less toxic than chemotherapy due to their more selective nature.

This study looks at almost all types of therapies/products used in oncology. The study conducts the prevalence of cancer globally. The research and development of new products and major changes in market behavior justify focusing on this segment. Finally, this study discusses the usage of these drug therapies by disease sector to determine the usage in each sector.

CONTRIBUTIONS of THE STUDY and for whom

The study contributes to the areas of market growth and decline in cancer therapies from the point of view of manufacturers and users. This study will be of interest largely to the pharmaceutical and biopharmaceutical industries, clinics, and hospitals.

SCOPE of the study

The scope of this study encompasses the markets for cancer therapies. BCC analyzes each market and its market leaders; different types of therapies; the prevalence of cancer; the regulatory environment; the different disease sectors for cancer; and market projections and market share. Technological issues include the latest trends and new developments

METHODOLOGY

Both primary and secondary sources were used for this research. A comprehensive literature search was conducted. The literature included technical newsletters and journals as well as many other sources. The data were collected through interviews and correspondence with various pharmaceutical/biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, likely unit prices, rates of consumption, and market trends.

INFORMATION SOURCES

BCC surveyed many companies to obtain data for this study. Included were manufacturers and end users of cancer drugs. We gathered the data; spoke with officials of this industry; and reviewed newsletters, company literature, product literature, a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were done. In addition, we compiled data from current financial and trade information and government sources.

TABLE OF CONTENTS

• Cancer Therapies: Technologies and Global Markets

Chapter- 1: SUMMARY

• SUMMARY TABLE THE GLOBAL CANCER THERAPY MARKET, THROUGH 2013 ($ MILLIONS)
• SUMMARY FIGURE THE GLOBAL CANCER THERAPY MARKET, 2006-2013 ($ MILLIONS)

Chapter- 2: OVERVIEW

• WHAT IS CANCER?
• CAUSES OF CANCER
• TYPES OF CANCER
• BLADDER CANCER
• Risk Factors
• Treatment
• BREAST CANCER
• Risk Factors
• Treatment
• Treatment (continued)
• COLORECTAL CANCER
• Risk Factors
• Treatment
• ENDOMETRIAL CANCER
• Risk Factors
• Treatment
• KIDNEY CANCER
• Risk Factors
• Treatment
• LEUKEMIA
• Risk Factors
• Treatment
• LUNG CANCER
• Risk Factors
• Treatment
• MELANOMA
• Risk Factors
• Treatment
• NON-HODGKIN'S LYMPHOMA
• Risk Factors
• Treatment
• PANCREATIC CANCER
• Risk Factors
• Treatment
• PROSTATE CANCER
• Risk Factors
• Treatment
• SKIN CANCER
• Risk Factors
• Treatment
• THYROID CANCER
• Risk Factors
• Treatment
• Treatment (Continued)

Chapter- 3: REGULATORY ISSUES

• NEW DRUG APPROVALS
  • TABLE 1 CANCER DRUGS APPROVED BY THE FDA
  • TABLE 1 (CONTINUED)
  • TABLE 1 (CONTINUED)
  • TABLE 1 (CONTINUED)
  • TABLE 1 (CONTINUED)
  • TABLE 1 (CONTINUED)
  • TABLE 1 (CONTINUED)
  • TABLE 1 (CONTINUED)
• NEW DRUG APPLICATIONS
  • TABLE 2 NEW DRUG APPLICATIONS (2005 TO JANUARY 2008)
• RECALLS
  • TABLE 3 RECALLS (2005 TO JANUARY 2008)
  • TABLE 3 (CONTINUED)
  • TABLE 3 (CONTINUED)

Chapter- 4: PREVALENCE

• WORLDWIDE PREVALENCE
  • TABLE 4 WORLDWIDE PREVALENCE OF CANCER, 2007 (MILLIONS)
  • TABLE 5 WORLDWIDE PREVALENCE OF NEW CASES OF CANCER, BY REGION, 2007
  • TABLE 6 WORLDWIDE DEATHS DUE TO CANCER, BY REGION, 2007
• PREVALENCE IN THE UNITED STATES
  • TABLE 7 ESTIMATED NEW CANCER CASES IN THE U.S., 2007
  • TABLE 8 CANCER DEATHS IN THE U.S., 2007
• PREVALENCE IN EUROPE
  • TABLE 9 ESTIMATED NEW CANCER CASES IN EUROPE, 2007
  • TABLE 10 CANCER DEATHS IN EUROPE, 2007

Chapter- 5: CLASSIFICATION OF CANCER THERAPIES

• CHEMOTHERAPY
• ALKYLATING AND ALKYLATING-LIKE AGENTS
  • TABLE 11 ALKYLATING AGENTS
• ANTIMETABOLITES
  • TABLE 12 ANTIMETABOLITES
• ANTHRACYCLINES
  • TABLE 13 CYTOTOXIC ANTIBIOTIC DRUGS
  • TABLE 13 (CONTINUED)
• PLANT ALKALOIDS
  • TABLE 14 ALKALOIDS/MITOTIC INHIBITORS
• TOPOISOMERASE INHIBITORS
  • TABLE 15 TOPOISOMERASE INHIBITORS
• BIOLOGICAL THERAPY OR IMMUNOTHERAPY
• INTERFERONS AND OTHER CYTOKINES
  • TABLE 16 INTERFERONS USED IN CANCER THERAPY
  • TABLE 17 INTERLEUKINS USED IN CANCER THERAPY
• CANCER VACCINES
• HORMONE THERAPY
• ANTIESTROGENS
  • TABLE 18 ANTIESTROGENS USED IN CANCER THERAPY
• AROMATASE INHIBITOR
  • TABLE 19 AROMATASE INHIBITORS USED IN THE TREATMENT OF CANCER
• ANTIANDROGENS
  • TABLE 20 ANTIANDROGENS USED IN CANCER TREATMENT
• LUTEINIZING HORMONE-RELEASING HORMONE
  • TABLE 21 LUTEINIZING HORMONE-RELEASING HORMONE USED IN THE TREATMENT OF CANCER
• TARGETED THERAPY
• SMALL MOLECULES/CANCER GROWTH INHIBITORS
  • TABLE 22 CANCER GROWTH INHIBITORS
  • TABLE 22 (CONTINUED)
• MONOCLONAL ANTIBODIES
• Conjugated
• Naked
  • TABLE 23 MONOCLONAL ANTIBODIES USED IN THE TREATMENT OF CANCER

Chapter- 6: INDUSTRY STRUCTURE

• CHEMOTHERAPY
• ALKYLATING AGENTS
  • TABLE 24 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ALKYLATING AGENTS, 2007 (%)
  • FIGURE 1 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ALKYLATING AGENTS, 2007 (%)
• ANTHRACYCLINES
  • TABLE 25 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTHRACYCLINES, 2007 (%)
  • FIGURE 2 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTHRACYCLINES, 2007 (%)
• PLANT ALKALOIDS
  • TABLE 26 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR PLANT ALKALOIDS, 2007 (%)
  • FIGURE 3 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR PLANT ALKALOIDS, 2007 (%)
• ANTIMETABOLITES
  • TABLE 27 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIMETABOLITES, 2007 (%)
  • FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIMETABOLITES, 2007 (%)
• TOPOISOMERASE
  • TABLE 28 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TOPOISOMERASE, 2007 (%)
  • FIGURE 5 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TOPOISOMERASE, 2007 (%)
• MARKET LEADERS OF CHEMOTHERAPY
  • TABLE 29 WORLDWIDE MARKET SHARE IN CHEMOTHERAPY, 2007 (%)
  • FIGURE 6 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CHEMOTHERAPY, 2007 (%)
• HORMONE THERAPY
• ANTIESTROGENS
  • TABLE 30 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS, 2007 (%)
  • FIGURE 7 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS, 2007 (%)
• ANTIANDROGENS
  • TABLE 31 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)
  • FIGURE 8 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIENDROGENS, 2007 (%)
• AROMATASE INHIBITORS
  • TABLE 32 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%)
  • FIGURE 9 SHARES OF MANUFCATURERS/DISTRIBUTORS FOR AROMATASE INHIBITOR, 2007 (%)
• LH-RH AGONIST INHIBITORS
  • TABLE 33 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH-RH AGONIST INHIBITORS, 2007 (%)
  • FIGURE 10 SHARES OF MANUFACTURERS/ DISTRIBUTORS FOR LH RH AGONIST INHIBITORS, 2007 (%)
• MARKET LEADERS OF HORMONE THERAPY
  • TABLE 34 WORLDWIDE MARKET SHARE IN HORMONE THERAPY, 2007 (%)
  • FIGURE 11 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR HORMONE THERAPY, 2007 (%)
• TARGETED THERAPY
• MONOCLONAL ANTIBODIES
  • TABLE 35 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR MONOCLONAL ANTIBODIES, 2007 (%)
  • FIGURE 12 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR MONOCLONAL ANTIBODIES, 2007 (%)
• SMALL MOLECULES
  • TABLE 36 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR SMALL MOLECULES, 2007 (%)
  • FIGURE 13 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR SMALL MOLECULES, 2007 (%)
• MARKET LEADERS OF TARGET THERAPY
  • TABLE 37 WORLDWIDE MARKET SHARE IN TARGET THERAPY, 2007 (%)
  • FIGURE 14 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TARGET THERAPY, 2007 (%)
• IMMUNOTHERAPY
• INTERFERON AND CYTOKINES
  • TABLE 38 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR INTERFERONS AND CYTOKINES, 2007 (%)
  • FIGURE 15 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR INTERFERONS AND CYTOKINES, 2007 (%)
• CANCER VACCINES
  • TABLE 39 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CANCER VACCINES, 2007 (%)
  • FIGURE 16 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CANCER VACCINES, 2007 (%)
• MARKET LEADERS OF IMMUNOTHERAPY
  • TABLE 40 WORLDWIDE MARKET SHARE IN IMMUNOTHERAPY, 2007 (%)
  • FIGURE 17 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR IMMUNOTHERAPY, 2007 (%)
• DEMAND AND USE
• FACTORS AFFECTING SALES OF CANCER DRUGS
• Competition
• Pricing/Cost
• MAJOR FACTORS FOR FUTURE GROWTH
• Life Expectancy
• Patent Protection
• Drug Portfolio Management
• Significant Potential of Developing Countries
• FUTURE OF THE CANCER MARKET
• Chemotherapy Will Sustain
• Targeted Therapy dominates
• Patent Expiries
• STRATEGIES OF BIG PHARMACEUTICAL COMPANIES
• Enhancement in Production Capacity:
• Market Strategy
• Mergers, Acquisitions, and Collaborations
• Further Investigations

Chapter- 7: MARKET ANALYSIS

• CHEMOTHERAPY
• CHEMOTHERAPY (CONTINUED)
• Market Size
  • TABLE 41 GLOBAL SALES OF DRUGS USED IN CHEMOTHERAPY, THROUGH 2013 ($ MILLIONS)
  • FIGURE 18 GLOBAL SALES OF DRUGS USED IN CHEMOTHERAPY, 2006-2013 ($ MILLIONS)
  • TABLE 42 GLOBAL MARKET SHARE OF CHEMOTHERAPY BY TYPE, 2007 (%)
  • FIGURE 19 GLOBAL MARKET SHARE OF CHEMOTHERAPY BY TYPE, 2007 (%)
• ALKYLATING AGENTS
  • TABLE 43 GLOBAL SALES OF ALKYLATING AGENTS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 20 GLOBAL SALES OF ALKYLATING AGENTS, 2006-2013 ($ MILLIONS)
• ANTHRACYCLINES
  • TABLE 44 GLOBAL SALES OF ANTHRACYCLINES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 21 GLOBAL SALES OF ANTHRACYCLINES, 2006-2013 ($ MILLIONS)
• PLANT ALKALOIDS
  • TABLE 45 GLOBAL SALES OF PLANT ALKALOIDS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 22 GLOBAL SALES OF PLANT ALKALOIDS, 2006-2013 ($ MILLIONS)
• ANTIMETABOLITES
  • TABLE 46 GLOBAL SALES OF ANTIMETABOLITES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 23 GLOBAL SALES OF ANTIMETABOLITES, 2006-2013 ($ MILLIONS)
• TOPOISOMERASE INHIBITORS
  • TABLE 47 GLOBAL SALES OF TOPOISOMERASE INHIBITORS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 24 GLOBAL SALES OF TOPISOMERASE INHIBITORS, 2006-2013 ($ MILLIONS)
• HORMONE THERAPY
• Market Size
  • TABLE 48 GLOBAL SALES OF HORMONE THERAPIES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 25 GLOBAL SALES OF HORMONE THERAPIES, 2006-2013 ($ MILLIONS)
  • TABLE 49 GLOBAL SHARE OF HORMONE THERAPY, BY TYPE, 2007 (%)
  • FIGURE 26 GLOBAL SHARE OF HORMONE THERAPY, BY TYPE, 2007 (%)
• ANTIESTROGENS
  • TABLE 50 GLOBAL SALES OF ANTIESTROGENS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 27 GLOBAL SALES OF ANTIESTROGENS, 2006-2013 ($ MILLIONS)
• ANTIANDROGENS
  • TABLE 51 GLOBAL SALES OF ANTIANDROGENS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 28 GLOBAL SALES OF ANTIANDROGENS, 2006-2013 ($ MILLIONS)
• AROMATASE INHIBITORS
  • TABLE 52 GLOBAL SALES OF AROMATASE INHIBITORS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 29 GLOBAL SALES OF AROMATASE INHIBITORS, 2006-2013 ($ MILLIONS)
• LH-RH AGONISTS
  • TABLE 53 GLOBAL SALES OF LH-RH AGONISTS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 30 GLOBAL SALES OF LH-RH AGONISTS, 2006-2013 ($ MILLIONS)
• TARGET THERAPIES
• Market Size
  • TABLE 54 GLOBAL SALES OF TARGET THERAPY CANCER PRODUCTS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 31 WORLDWIDE SALES OF TARGET THERAPY CANCER PRODUCTS, 2006-2013 ($ MILLIONS)
  • TABLE 55 GLOBAL SHARE OF TARGETED THERAPY, BY TYPE, 2007 (%)
  • FIGURE 32 GLOBAL SHARE OF TARGET THERAPY, BY TYPE, 2007 (%)
• MONOCLONAL ANTIBODIES
  • TABLE 56 GLOBAL SALES OF MONOCLONAL ANTIBODIES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 33 GLOBAL SALES OF MONOCLONAL ANTIBODIES, 2006-2013 ($ MILLIONS)
• SMALL MOLECULES
  • TABLE 57 GLOBAL SALES OF SMALL MOLECULES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 34 GLOBAL SALES OF SMALL MOLECULES, 2006-2013 ($ MILLIONS)
• IMMUNOTHERAPY
• Market Size
  • TABLE 58 GLOBAL SALES OF IMMUNOTHERAPY PRODUCTS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 35 WORLDWIDE SALES OF IMMUNOTHERAPY PRODUCTS, 2006-2013 ($ MILLIONS)
  • TABLE 59 GLOBAL REVENUE SHARE OF IMMUNOTHERAPY BY TYPE, 2007 (%)
  • FIGURE 36 GLOBAL SHARE OF IMMUNOTHERPY, BY TYPE, 2007 (%)
• INTERFERONS AND CYTOKINES
  • TABLE 60 GLOBAL SALES OF INTERFERONS AND CYTOKINES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 37 GLOBAL SALES OF INTERFERONS AND CYTOKINES, 2006-2013 ($ MILLIONS)
• VACCINES
  • TABLE 61 GLOBAL SALES OF CANCER VACCINES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 38 GLOBAL SALES OF CANCER VACCINES, 2006-2013 ($ MILLIONS)

Chapter- 8: NEW DEVELOPMENTS

• NEW DEVELOPMENTS
  • TABLE 62 CANCER DRUG PIPELINE IN PHASE III CLINICAL TRIALS
  • TABLE 62 (CONTINUED)
  • TABLE 62 (CONTINUED)
  • TABLE 62 (CONTINUED)
• TARGET
  • TABLE 63 CANCER DRUG PIPELINE IN PHASE II CLINICAL TRIALS
  • TABLE 63 (CONTINUED)
  • TABLE 63 (CONTINUED)
  • TABLE 63 (CONTINUED)
  • TABLE 64 CANCER DRUG PIPELINE IN PHASE I CLINICAL TRIALS
  • TABLE 64 (CONTINUED)
  • TABLE 64 (CONTINUED)

Chapter- 9: MARKET BY DISEASE TYPE

• TABLE 65 GLOBAL SALES OF CANCER THERAPY BY TYPE OF CANCER, THROUGH 2013 ($ MILLIONS)
• FIGURE 39 GLOBAL SALES OF CANCER THERAPY BY TYPE OF CANCER, 2006-2013 ($ MILLIONS)
• TABLE 66 MARKET SHARE OF VARIOUS TYPES OF CANCER, 2007 (%)
• FIGURE 40 MARKET SHARE OF VARIOUS TYPES OF CANCER, 2007 (%)
• BREAST CANCER THERAPY
  • TABLE 67 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN BREAST CANCER TREATMENT, 2007 ($ MILLION/%)
  • FIGURE 41 SALES OF VARIOUS THERAPIES USED IN BREAST CANCER TREATMENT, 2007 ($ MILLIONS)
  • TABLE 68 WORLDWIDE MARKET SHARE OF COMPANIES FOR BREAST CANCER THERAPY REVENUE, 2007 (%)
  • FIGURE 42 WORLDWIDE MARKET SHARE OF COMPANIES FOR BREAST CANCER THERAPY REVENUE, 2007 (%)
• COLORECTAL CANCER
  • TABLE 69 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN COLORECTAL CANCER TREATMENT, 2007 ($ MILLION/%)
  • FIGURE 43 SALES OF VARIOUS THERAPIES USED IN COLORECTAL CANCER TREATMENT, 2007 ($ MILLIONS)
  • TABLE 70 WORLDWIDE MARKET SHARE OF COMPANIES IN COLORECTAL CANCER THERAPY REVENUE, 2007 (%)
  • FIGURE 44 WORLDWIDE MARKET SHARE OF COMPANIES IN COLORECTAL CANCER THERAPY REVENUE, 2007 (%)
• PROSTATE CANCER
  • TABLE 71 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN PROSTATE CANCER TREATMENT, 2007 ($ MILLION/%)
  • FIGURE 45 SALES OF VARIOUS THERAPIES USED IN PROSTATE CANCER TREATMENT, 2007 ($ MILLIONS)
  • TABLE 72 WORLDWIDE MARKET SHARE OF COMPANIES IN PROSTATE CANCER THERAPY REVENUE, 2007 (%)
  • FIGURE 46 WORLDWIDE MARKET SHARE OF COMPANIES IN PROSTATE CANCER THERAPY REVENUE, 2007 (%)
• NONSMALL CELL LUNG CANCER
  • TABLE 73 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN NONSMALL CELL LUNG CANCER TREATMENT, 2007 ($ MILLIONS/%)
  • FIGURE 47 GLOBAL SALES OF VARIOUS THERAPIES USED IN NONSMALL CELL LUNG CANCER TREATMENT, 2007 ($ MILLIONS)
  • TABLE 74 GLOBAL MARKET SHARE OF COMPANIES IN NON SMALL CELL LUNG CANCER THERAPY REVENUE, 2007 (%)
  • FIGURE 48 WORLDWIDE MARKET SHARE OF COMPANIES IN NON SMALL CELL LUNG CANCER THERAPY REVENUE, 2007 (%)
• HEAD AND NECK CANCER
  • TABLE 75 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN HEAD AND NECK CANCER TREATMENT, 2007 ($ MILLION/%)
  • FIGURE 49 GLOBAL SALES OF VARIOUS THERAPIES USED IN HEAD AND NECK CANCER TREATMENT, 2007 ($ MILLIONS)
  • TABLE 76 WORLDWIDE MARKET SHARE OF COMPANIES IN HEAD AND NECK CANCER THERAPY REVENUE, 2007 (%)
  • FIGURE 50 WORLDWIDE MARKET SHARE OF COMPANIES IN HEAD AND NECK CANCER THERAPY REVENUE, 2007 (%)
• RENAL CELL CARCINOMA
  • TABLE 77 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN RENAL CELL CARCINOMA TREATMENT, 2007 ($ MILLIONS/%)
  • FIGURE 51 GLOBAL SALES OF VARIOUS THERAPIES USED IN RENAL CELL CARCINOMA TREATMENT, 2007 ($ MILLIONS)
  • TABLE 78 GLOBAL MARKET SHARE OF COMPANIES IN RENAL CELL CARCINOMA THERAPY REVENUE, 2007 (%)
  • FIGURE 52 GLOBAL MARKET SHARE OF COMPANIES IN RENAL CELL CARCINOMA THERAPY REVENUE, 2007 (%)
• PANCREATIC CANCER THERAPY
  • TABLE 79 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN PANCREATIC CANCER TREATMENT, 2007 ($ MILLION/%)
  • FIGURE 53 GLOBAL SALES OF VARIOUS THERAPIES USED IN PANCREATIC CANCER TREATMENT, 2007 ($ MILLIONS)
  • TABLE 80 GLOBAL MARKET SHARE OF COMPANIES IN PANCREATIC CANCER THERAPY REVENUE, 2007 (%)
  • FIGURE 54 GLOBAL MARKET SHARE OF COMPANIES IN PANCREATIC CANCER THERAPY REVENUE, 2007 (%)

Chapter- 10: PATENT ANALYSIS

• TOTAL PATENTS
• PATENTS BY YEAR
  • TABLE 81 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2008
  • FIGURE 55 NUMBER OF PATENTS, 2005-2008
• PATENTS BY TYPE
  • TABLE 82 NUMBER OF PATENTS BY TYPE, 2005-2008
  • FIGURE 56 NUMBER OF PATENTS BY TYPE, 2005-2008 (NO. OF PATENTS)
  • FIGURE 57 NUMBER OF PATENTS, SHARE BY TYPE, 2005-2008 (%)
• PATENTS BY COUNTRY
  • TABLE 83 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008
  • TABLE 83 (CONTINUED)
• PATENTS BY COMPANY
  • TABLE 84 NUMBER OF PATENTS BY COMPANY, 2005-2008
  • TABLE 84 (CONTINUED)
  • TABLE 84 (CONTINUED)
• PATENTS BY ASSIGNEE
  • TABLE 85 NUMBER OF PATENTS BY ASIGNEE, 2005-2008

Chapter- 11: COMPANY PROFILES

• ABRAXIS BIOSCIENCES, INC.
• AMGEN INC.
• ASTRAZENECA PLC
• BIOGEN IDEC
• BRISTOL-MYERS SQUIBB
• CELGENE CORP.
• CEPHALON INC.
• CHUGAI PHARMACEUTICAL CO., LTD.
• ELI LILLY AND CO.
• GENENTECH INC.
• GENENTECH INC. (CONTINUED)
• GENZYME CORP.
• GLAXOSMITHKLINE PLC
• GPC BIOTECH AG
• IMCLONE SYSTEMS, INC.
• INFINITY PHARMACEUTICALS, INC.
• MERCK & CO.
• NOVARTIS
• OSI PHARMACEUTICALS, INC.
• PFIZER INC.
• PROGEN PHARMACEUTICALS, LTD.
• ROCHE
• SANOFI-AVENTIS
• SCHERING-PLOUGH
• SEATTLE GENETICS, INC.
• TAP PHARMACEUTICAL PRODUCTS, INC.
• TAIHO PHARMACEUTICALS CO., LTD.
• WYETH
• YM BIOSCIENCES, INC.

Chapter- 12: APPENDIX

• APPENDIX
• APPENDIX (CONTINUED)